(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Nov. 12, 2026 (GLOBE NEWSWIRE) -- "Thin Film Drug Manufacturing - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global thin film drug manufacturing market was valued at US$8 billion in 2025 and is projected to reach US$14.3 billion by 2032, expanding at a compound annual growth rate (CAGR) of 8.6%. Market growth is being supported by rising demand for advanced drug delivery systems, patient-centric pharmaceutical formulations, personalized medicine, and scalable manufacturing technologies.
Thin film formulations are gaining traction across oral, transdermal, ocular, and other delivery routes because of their rapid dissolution, improved absorption, flexible dosing, and potential to enhance bioavailability. Their convenience also supports medication adherence, particularly among elderly patients, people with mobility limitations, and patients managing chronic conditions that require frequent or long-term treatment.
Thin Film Drug Manufacturing Market Trends and Growth Drivers
Pharmaceutical companies are increasing investments in thin film drug delivery technologies to improve therapeutic performance and address limitations associated with conventional dosage forms. These formulations can support faster onset of action, controlled or sustained release, and targeted delivery. Their compatibility with poorly soluble compounds and selected biologics is also expanding potential applications across pain management, cardiovascular disease, oncology, schizophrenia, migraine, and opioid dependence.
The rising prevalence of chronic diseases is another important market driver. Conditions such as diabetes, hypertension, and cancer frequently involve complex treatment regimens, making adherence a significant concern. Thin film products can simplify administration and eliminate the need for water in certain applications, helping pharmaceutical manufacturers create more convenient treatment options.
Growth opportunities are also emerging in developing economies as healthcare infrastructure improves and access to pharmaceutical products expands. Manufacturers are evaluating affordable thin film formulations designed to address unmet medical needs while meeting regional requirements for accessibility, stability, and ease of administration.
Technology and Manufacturing Innovation
Advances in solvent casting, hot-melt extrusion, coating systems, roll-to-roll processing, and continuous manufacturing are improving control over film thickness, uniformity, drug loading, and production efficiency. These technologies are helping manufacturers scale output while maintaining product quality and consistency.
Nanotechnology, advanced polymers, and novel excipients are further strengthening formulation capabilities. Nanomaterials can improve the solubility and bioavailability of certain active pharmaceutical ingredients, while specialized polymers can optimize immediate, controlled, or sustained release profiles. These developments are broadening the role of thin film drug delivery in personalized medicine and targeted therapies.
Analytical and quality-control technologies remain critical to commercialization. High-performance liquid chromatography, scanning electron microscopy, and differential scanning calorimetry are among the methods used to evaluate formulation characteristics and support compliance with pharmaceutical safety, efficacy, and consistency requirements.
Research, Collaboration, and Personalized Medicine
Collaboration among pharmaceutical companies, biotechnology firms, academic institutions, and research organizations is accelerating thin film product development. These partnerships facilitate access to specialized expertise, advanced materials, and manufacturing platforms while helping participants address technical and regulatory challenges.
Personalized medicine is also creating demand for adaptable drug delivery formats. Thin films offer flexibility in dosage, formulation design, release profile, and administration route, making them suitable for therapies tailored to specific patient requirements. Continued investment in research and development is expected to expand the number of therapeutic applications and strengthen the global commercial pipeline.
Market Segment and Regional Outlook
Oral thin films: This segment is projected to reach US$6.3 billion by 2032, advancing at a CAGR of 8.4%. Transdermal thin films: The segment is forecast to record a CAGR of 10.4% during the analysis period. United States: The U.S. thin film drug manufacturing market was valued at US$2.4 billion in 2025. China: The Chinese market is projected to grow at a CAGR of 8.3% and reach US$2.5 billion by 2032. Additional markets: The report evaluates trends in Canada, Japan, Germany, France, Italy, the United Kingdom, the wider Asia-Pacific region, and the Rest of World.
Report Scope
The report analyzes the global thin film drug manufacturing market by value and provides annual sales estimates and forecasts from 2025 through 2032.
By type: Oral thin films, transdermal thin films, and other thin film types. By distribution channel: Hospital pharmacies, drug stores, retail pharmacies, and e-commerce. By indication: Schizophrenia, migraine, opioid dependence, and other indications. By geography: United States, Canada, Japan, China, Europe, Asia-Pacific, Latin America, the Middle East, Africa, and Rest of World.
Key Report Benefits
Independent market forecasts and analysis of the factors influencing global demand through 2032. Evaluation of high-growth product types, therapeutic indications, distribution channels, and geographic markets. Competitive intelligence covering major participants and their presence across key regions. Analysis of emerging technologies, research priorities, collaborations, and commercialization opportunities. Actionable insights designed to support strategic planning, investment assessment, product development, and market-entry decisions. Complimentary report updates for one year.
Companies Featured
Allergan plc Indivior plc IntelGenx Corp. MonoSol Rx Novartis AG Pfizer, Inc. Solvay Sumitomo Dainippon Pharma Co., Ltd. Wolters Kluwer ZIM Laboratories Limited
Domain Expert Insights and Differentiators
The report incorporates perspectives from industry specialists, enterprise leaders, researchers, and academic experts to provide context beyond conventional published research. The report tracks early market signals emerging from expert discussions, corporate activity, conference sessions, keynote presentations, panel discussions, regulatory developments, institutional publications, annual reports, and other validated sources.
These inputs are synthesized to identify the direction of the thin film drug manufacturing market, the forces shaping adoption, and the developments most likely to influence corporate strategy. The analysis also extends beyond global market estimates to examine participating companies and regional competitive structures. Where analytically relevant, market share is assessed at the regional level to reflect differences in competitive conditions, commercial maturity, and market dynamics.
Key Attributes
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment